Chronic liver disease poses a growing global health burden, driven in large part by metabolic risk factors and viral hepatitis. Fibrosis stage is the principal ...

Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) ...

Non-invasive biomarkers and scoring systems demonstrated effectiveness in differentiating chronic liver disease (CLD) from cirrhosis; non-invasive fibrosis scores such as the Lok index, King's score, ...

Assessment of liver function has been revolutionised by non-invasive approaches that avoid the risks and discomfort of biopsy. Broadly, these techniques fall into three categories: serological panels, ...

Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO-a certified algorithm de ...

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development This is the first time the FDA is ...

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...

Focused ultrasound creates precise mechanical cavitation that liquefies tumor tissue while sparing adjacent parenchyma, avoiding thermal sink effects and reducing risk near major vessels and bile ...